Last reviewed · How we verify

NCT03190018

A Feasibility Study of Peritoneal Dialysis With CLS PD, Which Removes Toxins and Maintains a Stable Ultrafiltration by Continuously Regenerating a Recirculating Intraperitoneal Fluid, in Patients With End Stage Renal Disease, ESRD, With PD Therapy.

Completed NA Last updated 17 April 2018
What this trial tests

NA trial testing lCarry Life System Peritoneal Dialysis (CLS PD) in Peritoneal Dialysis in 5 participants. Completed in 31 March 2018.

Timeline
1 June 2017
Primary endpoint
13 March 2018
31 March 2018

Quick facts

Lead sponsorTriomed AB
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment5
Start date1 June 2017
Primary completion13 March 2018
Estimated completion31 March 2018
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Triomed AB — full company profile →

Who can join

18 and older, any sex, with Peritoneal Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a proof-of-concept of peritoneal dialysis with the Carry Life System for Peritoneal Dialysis (CLS PD). The extra-corporeally absorption of uremic toxins and certain ions from the recirculated peritoneal fluid by the Purcart are evaluated together with the achievement of a stable intraperitoneal osmolarity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Peritoneal Dialysis

Currently open trials in the same condition.

Other Triomed AB trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03190018.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing